Le Lézard
Classified in: Health
Subjects: MAT, MRR

Cannabidiol (CBD) API Market to Record Rapid Growth with CAGR of 41.7% by 2030 - Exclusive Report by InsightAce Analytic

JERSEY CITY, N.J., Dec. 1, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Cannabidiol (CBD) API Market By Product (Full spectrum CBD, Broad-spectrum CBD, CBD isolate, Water Dispersible CBD Powder, Others), Origin(Natural, Synthetic), Indication (Alzheimer's Disease, Autism, Cancer, Chronic Pain, Epilepsy, Migraine, Multiple Sclerosis, Schizophrenia, Others), End-Users (Pharmaceutical Industry, Research Institutes, Others))- Market Outlook and Industry Analysis 2030".

InsightAce Analytic Logo

According to company's newly published research report, the global Cannabidiol (CBD) API market is predicted to register a promising CAGR of 41.7%  between 2022 and 2030. The major prominent players operating in the market are Recipharm, brains bioceutical, Purisys, DSM, Bedrocan, CBD API, Vantage Hemp, Eurofins, Farmakem d.o.o., Kare Chemical Technologies Inc., CBDepot s.r.o, BIOVECTRA Inc., EndoPure, Biosyyd, UAB, KD Pharma Group, Folium Biosciences, Kinetochem, Colombian Golden, Averix Bio, LLC, Veranova, KND Labs, Jordan Process, GVB Biopharma, and Other vital players.

Get a Demo Sample copy of the Report at  https://www.insightaceanalytic.com/request-sample/1478 

CBD, often known as cannabidiol, is the second most prevalent active component in cannabis (marijuana). CBD, an essential element of medical marijuana, is extracted directly from the hemp plant, a relative of marijuana, or synthesised in a laboratory. CBD, one of the hundreds of components found in marijuana, does not generate a "high" by itself. In accordance with research by the World Health Organization, "CBD has no psychoactive or habit-forming effects in humans. There are now no indications that the consumption of pure CBD poses any risks to public health." CBD has been recommended for a range of health conditions. Still, the best scientific evidence is for its efficacy in treating some of the worst childhood epilepsy disorders, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), which often do not respond to anticonvulsant drugs. Several neurological illnesses have been the subject of cannabidiol research. However, the findings have not been verified to establish such uses in clinical practice. The FDA issued an advisory warning in October 2019 that the effects of CBD during pregnancy or nursing are unknown, indicating that CBD's safety, dosages, interactions with other medications or foods, and side effects are not clinically established and may constitute a risk to the mother and newborn. In a number of studies, CBD was able to lower the frequency of seizures and, in some circumstances, halt them entirely. Epidiolex, containing CBD, is the first FDA-approved drug produced from cannabis for these disorders.

Demand for CBD for health and wellness is expected to drive the market growth. CBD relieves anxiety, seizures, and pain. Cannabidiol, the cannabinoid most widely utilised for therapeutic purposes, is in high demand for health and wellness due to its lack of psychoactive effects. The growing acceptance and use of products due to regulatory approvals are also expected to boost CBD-infused product production. CBD as an API will also benefit from government financing for therapeutic research and partnerships with major market players. A boost in hoarding events by pharmacies, exclusive agreements between companies and retail pharmacies, and a rise in the number of patients opting for CBD treatment is anticipated to create substantial prospects for market participants in the CBD market.

The FDA is cautiously authorising CBD-derived drugs due to the sensitivity of CBD as a medicinal chemical ingredient. Delays in approvals will negatively impact the CBD API market. This market's high price is the greatest obstacle for them. Due to their medical benefits and extensive research requirements, the majority of people cannot afford them. This impedes the expansion of CBD businesses.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1478 

The Key developments

Market Segments

Global Cannabidiol (CBD) API Market, by Product, 2022-2030 (Value US$ Mn)

Global Cannabidiol (CBD) API Market, by Origin, 2022-2030 (Value US$ Mn)

Global Cannabidiol (CBD) API Market, by Indication, 2022-2030 (Value US$ Mn)

Global Cannabidiol (CBD) API Market, by End-User, 2022-2030 (Value US$ Mn)

Global Cannabidiol (CBD) API Market, by Region, 2022-2030 (Value US$ Mn)

North America Cannabidiol (CBD) API Market, by Country, 2022-2030 (Value US$ Mn)

Europe Cannabidiol (CBD) API Market, by Country, 2022-2030 (Value US$ Mn)

Asia Pacific Cannabidiol (CBD) API Market, by Country, 2022-2030 (Value US$ Mn)

Latin America Cannabidiol (CBD) API Market, by Country, 2022-2030 (Value US$ Mn)

Middle East & Africa Cannabidiol (CBD) API Market, by Country, 2022-2030 (Value US$ Mn)

For More Information @ https://www.insightaceanalytic.com/customisation/1478            

Why should buy this report:

Other Related Reports Published by InsightAce Analytic:

Global Cannabinoid Derived Pharmaceutical Market Assessment

Global CBD (Cannabidiol ) Oil Market

Cannabis Inhaler Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic Pvt. Ltd. 
Tel.: +1 551 226 6109
Email: [email protected]
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

These press releases may also interest you

at 07:50
Aptinyx Inc. , a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a...

at 07:47
The Make-A-Wish America National Board of Directors gets even stronger with the addition of Michelle Wilson, founder and co-CEO of Isos Capital Management, and Stan Moss, CEO of Polen Capital. As leaders of their respective investment firms, Wilson...

at 07:47
According to VRMNY, Karen Medina is the new Chief Operating Officer. Karen comes from over 15 years of experience in the healthcare industry, including expertise in strategic planning, financial management, and team building. She has a proven track...

at 07:37
Leading nutrition tracking app, Cronometer, will now integrate with Dexcom, the global leader in real-time continuous glucose...

at 07:37
According to The Business Research Company's Precision Medicine Global Market Report 2023, the competitive landscape of global precision medicine market is fairly fragmented, with a large number of players. The top ten competitors in the market made...

at 07:30
Medicenna Therapeutics Corp. ("Medicenna" or "the Company") , a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023...

News published on 1 december 2022 at 05:45 and distributed by: